Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic User Fees Might Combine Inspection Visits, Boost Foreign Cooperation

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency outlines ideas for coordinating and combining different types of facility inspections in generic drug user fee negotiations, while industry asks how it will affect collaboration with international regulators.

You may also be interested in...



Collaboration On Foreign Inspections Helps FDA Improve Resource Allocations

FDA better allocated resources for foreign inspections based on information European and Australian authorities shared in a two-year pilot program, including conducting good manufacturing practices inspections that met the needs of multiple agencies.

Collaboration On Foreign Inspections Helps FDA Improve Resource Allocations

FDA better allocated resources for foreign inspections based on information European and Australian authorities shared in a two-year pilot program, including conducting good manufacturing practices inspections that met the needs of multiple agencies.

GMP Oversight Collaboration Helps FDA Plan, But Not Avoid, Foreign Inspections

FDA has improved planning efforts with information borrowed from European and Australian authorities, but an inspection collaboration between the three countries could not help it avoid some inspections.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072255

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel